Oxford, Not a few people who consume drugs to fight the thinning of the bones to avoid osteoporosis. But according to the study, taking osteoporosis drugs may increase cancer risk.
Experts warn that the osteoporosis drug can be two times increased risk of esophageal cancer or esophageal cancer.
Reporting from Dailymail, Monday (06/09/2010), a study showed that people who take oral bisphosphonate drugs (osteoporosis drugs) for 5 years, ie the duration is recommended to increase bone strength, are at high risk of esophageal cancer.
Oral bisphosphonates are the type of medicine used to treat osteoporosis and other bone diseases. Oral bisphosphonates is also the most frequently recommended treatment for bone thinning condition.
It is estimated that, with the risk of the drug mengosumsi gastric reflux is very large, ie stomach acid rises and flows back into the esophagus, especially the food channel. This condition can cause pre-cancerous changes.
Researchers from the Cancer Epidemiology Unit, University of Oxford and the Governing Body British Medicines and Health Products (Medicines and Healthcare products Regulatory Agency or MHRA) analyzed data from the UK General Practice Research Database.
Researchers focus on men and women aged over 40 years who consumed oral bisphosphonates (including Fosamax) and its relation to three types of cancer, namely esophageal cancer, stomach cancer and colon cancer, between 1995 and 2005.
The result, researchers found that people who consumed 10 or more prescription drugs for osteoporosis for about three to five years, nearly twice the risk of esophageal cancer compared with people who do not eat at all.
In general, esophageal cancer usually develops in 1 in 1000 people aged 60-79 years during the five years. But with the use of prophylactic bone thinning medication, this risk increased to two cases per 1000 people.
The results of this study have been published in the British Medical Journal.
No comments:
Post a Comment